SPONSOR
Jiangsu Cancer Institute & Hospital
Total Trials
3
Recruiting
3
Phases
Phase 2
Conditions studied: Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaGastroesophageal AdenocarcinomaGastric AdenocarcinomaNon-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Non-small Cell Lung Cancer.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Jiangsu Cancer Institute & Hospital
How many clinical trials has Jiangsu Cancer Institute & Hospital sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Jiangsu Cancer Institute & Hospital, of which 3 are actively recruiting participants. These trials cover conditions including Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Jiangsu Cancer Institute & Hospital research focus on?
Jiangsu Cancer Institute & Hospital clinical trials span Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Non-small Cell Lung Cancer. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Jiangsu Cancer Institute & Hospital clinical trial?
To participate in a Jiangsu Cancer Institute & Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Jiangsu Cancer Institute & Hospital trials with current recruitment status updated daily.
Clinical Trials by Jiangsu Cancer Institute & Hospital
NCT07435454 Phase 2
Recruiting
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
NCT06985602 Phase 2
Recruiting
Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Gastroesophageal Adenocarcinoma
NCT06198868
Recruiting
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
Non-small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology